CEO/President Charles Fitzgerald put in $1.28M on Aug 10, raising his stake 28% — second insider buying alongside, so a real 2-person C-suite cluster. Clean net flow, buy price ($35.94) essentially at current ($36.42), profitable medical REIT with solid FFO of $1.04/share and stable 95%-leased outpatient portfolio; sits 25% off its 52w low, RSI 43, but just below MA20/50 keeps it from A+. Real estate sector is lagging SPY by ~4% and 633M debt vs 10M cash is the main watch-out.
Watch: Sector lagging SPY (-4.4%); high leverage (633M debt vs 11M cash); slightly below MA20/MA50.